# US 2025/0154494 A1 · Microfluidic Co-Encapsulation Device and System and Methods for Identifying T-Cell Receptor Ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154494 A1
- Document ID: US20250154494A1
- Status: Published application
- Kind: A1
- Application number: 18/708,079
- Filed: 2022-11-08
- Published: 2025-05-15
- Earliest claimed: 2021-11-09
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Nathan Felix; John M. Lindner; Kristina Kromer; Constantin Diekmann; Yonatan Herzig; Veronica Pinamonti; Miguel A. Hernandez; Miray Cetin; Jing Zhang; Laura Fisch
- Web page: https://patentgrep.com/patent/US20250154494A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12M 25/16: {Particles; Beads; Granular material; Encapsulation (chemical or physical processes conducted in the presence of fluids and solid particles B01J8/00)}
- C12M 29/06: {Nozzles; Sprayers; Spargers; Diffusers (per se B01F23/231, B01J19/26)}
- C12N 5/0635: {B lymphocytes}
- C12N 5/0636: {T lymphocytes}
- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a platform for co-culturing T cells with APC cells expressing a library of antigenic sequences is disclosed, as well as compositions for use in the system, a co-culturing device and methods of use of the system for identifying novel T cell receptor:antigen interactions. The present invention also provides microfluidic co-encapsulation devices configured to generate longitudinal flows of individual particles (such as individual cells) from fluid particle suspensions, combining two or more individual particle flows into a single stream of individual particles, and segmenting the single stream using an isolation fluid, resulting in a suspension of co-encapsulated individual particles from each fluid particle suspension. The present invention also provides methods of using the microfluidic co-encapsulation devices and methods of modifying fluid particle suspensions to promote individual particle separation.

## Claims

### Claim 1

A method of identifying an antigenic polypeptide as a ligand for binding by a T cell receptor (TCR), the method comprising:
a) co-culturing at least one cell comprising:
i) at least one TCR and
ii) a nucleic acid molecule comprising a TCR responsive promoter operably linked to an expression cassette comprising a nucleotide sequence encoding a marker,
with one or more antigen presenting cell (APC) of an APC library comprising a plurality of APCs, wherein each APC comprises a nucleic acid molecule of a minigene library comprising a plurality of nucleic acid molecules wherein each nucleic acid molecule comprises a nucleotide sequence encoding at least one antigenic polypeptide for presentation as an antigenic polypeptide-human leukocyte antigen (HLA) complex, wherein the sequence encoding the at least one antigenic polypeptide is of a predetermined length;
wherein binding of the TCR to at least one antigenic polypeptide-HLA complex of the APC induces expression of the nucleic acid molecule encoding the marker;
b) isolating the APC cell bound to the cell comprising the TCR; and
c) sequencing the nucleic acid molecule of the minigene library of the APC cell to identify the antigenic polypeptide as a ligand for binding by the TCR.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expression cassette comprises a nucleotide sequence encoding a marker selected from the group consisting of a fluorescent marker and an antibody, or fragment thereof, specific for binding to an APC marker.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the method of co-culturing comprises applying the at least one cell expressing a TCR to a first inlet of a microfluidic co-culture device comprising two inlets and applying the APC library to a second inlet of the microfluidic co-culture device.

### Claim at position 5

-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the TCR responsive promoter comprises a sequence selected from the group consisting of SEQ ID NO:50-SEQ ID NO:74.

### Claim at position 7

-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the nucleic acid molecule of the minigene library further comprises a sequence encoding at least one transmembrane domain, or fragment thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the transmembrane domain is selected from the group consisting of SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO: 124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:135.

### Claim at position 10

-67. (canceled)

### Claim 68

A microfluidic device for co-encapsulation of individual cells, comprising:
two or more proximal inlets fluidly connected to one or more distal outlets;
a filter positioned downstream from each proximal inlet;
a series of asymmetrical focusing loops positioned downstream from each filter;
a nozzle positioned upstream from the one or more distal outlets; and
one or more isolation fluid inlets connected to the nozzle;
wherein each of the series of asymmetrical focusing loops comprise arcuate channel lengths curving in alternating directions about a central axis, such that arcuate channel lengths on a first side of the central axis are larger than arcuate channel lengths on an opposing second side of the central axis; and
wherein each of the series of asymmetrical focusing loops converge into a single microchannel fluidly connected to the nozzle.

### Claim at position 12

-93. (canceled)

### Claim 94 (depends on 68)

The device of claim 68, wherein the device further comprises one or more additional inlets fluidly connected directly to or to a position between one or more of the proximal inlets, filters, focusing loops, nozzle, and outlet.

### Claim 95

(canceled)

### Claim 96 (depends on 68)

A method of forming co-encapsulated particles, comprising the steps of:
providing the device of claim 68;
providing a first suspension of a particle;
providing at least one second suspension of a particle;
flowing each of the suspensions through a proximal inlet of the device; and
flowing an isolation fluid through an isolation fluid inlet of the device.

### Claim 97 (depends on 96)

The method of claim 96, wherein the particle of the first suspension and the at least one second suspension is selected from the group consisting of: cells, viruses, bacteria, amoeba, protozoa, paramecium, microparticles, nanoparticles, beads, microorganisms, vesicles, nucleic acid oligonucleotides, proteins, polypeptides, carbohydrates, and fragments thereof.

### Claim 98 (depends on 97)

The method of claim 97, wherein the first suspension and the at least one second suspension comprises a suspension fluid selected from the group consisting of: water, cell growth media, serum, plasma, and oil.

### Claim 99 (depends on 98)

The method of claim 98, wherein the isolation fluid is immiscible with the suspension fluid.

### Claim 100 (depends on 97)

The method of claim 97, wherein the particle of the first suspension is a B cell.

### Claim at position 20

-104. (canceled)

### Claim 105 (depends on 97)

The method of claim 97, wherein the particle of the at least one second suspension is a T cell.

### Claim at position 22

-109. (canceled)

### Claim 110

A nucleic acid molecule encoding an antibody or fragment thereof specific for binding to an antigen-presenting cell (APC) marker selected from the group consisting of CD19 and CD20, wherein the nucleic acid molecule comprises at least one selected from the group consisting of:
a) a nucleotide sequence encoding a heavy chain variable region of an anti-CD19 synthetic antibody selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:12;
b) a nucleotide sequence encoding a light chain variable region of an anti-CD19 synthetic antibody selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:16;
c) a nucleotide sequence encoding a heavy chain variable region of an anti-CD20 synthetic antibody selected from the group consisting of SEQ ID NO:20 and SEQ ID NO:28; and
d) a nucleotide sequence encoding a light chain variable region of an anti-CD20 synthetic antibody selected from the group consisting of SEQ ID NO:24 and SEQ ID NO:32.

### Claim 111 (depends on 110)

The nucleic acid molecule of claim 110, encoding an scFV antibody fragment selected from the group consisting of:
a) a nucleotide sequence encoding a heavy chain variable region of an anti-CD19 synthetic antibody comprising SEQ ID NO:4 and a light chain variable region of an anti-CD19 synthetic antibody comprising SEQ ID NO:8;
b) a nucleotide sequence encoding a heavy chain variable region of an anti-CD19 synthetic antibody comprising SEQ ID NO:12 and a light chain variable region of an anti-CD19 synthetic antibody comprising SEQ ID NO:16;
c) a nucleotide sequence encoding a heavy chain variable region of an anti-CD20 synthetic antibody comprising SEQ ID NO:20 and a light chain variable region of an anti-CD20 synthetic antibody comprising SEQ ID NO:24; and
d) a nucleotide sequence encoding a heavy chain variable region of an anti-CD20 synthetic antibody comprising SEQ ID NO:28 and a light chain variable region of an anti-CD20 synthetic antibody comprising SEQ ID NO:32.

### Claim 112

(canceled)

### Claim 113 (depends on 110)

The nucleic acid molecule of claim 110, wherein the nucleic acid molecule comprises a nucleotide sequence encoding at least two tandem scFv molecules separated by a linker sequence.

### Claim 114

A nucleic acid molecule comprising a nucleotide sequence encoding at least one antigenic polypeptide for presentation at a cell surface, and further comprising at least one transmembrane sequence for enhanced presentation, or fragment thereof.

### Claim 115 (depends on 114)

The nucleic acid molecule of claim 114, wherein the transmembrane domain is selected from the group consisting of SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO: 128, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:135.

### Claim at position 29

-117. (canceled)

### Claim 118 (depends on 114)

An immunogenic composition comprising at least one nucleic acid molecule comprising a nucleotide sequence encoding at least one antigenic polypeptide for presentation at a cell surface, and further comprising at least one transmembrane sequence for enhanced presentation of claim 114.

### Claim at position 31

-121. (canceled)
